Your browser doesn't support javascript.
Side effects of lopinavir/ritonavir for COVID-19
Chinese Journal of Clinical Pharmacology and Therapeutics ; 25(11):1283-1287, 2020.
Article in Chinese | EMBASE | ID: covidwho-1024781
ABSTRACT

AIM:

To study the regularity and characteristics of side effects of lopinavir/ritonavir for COVID-19.

METHODS:

The type of side effects, general information, medical history and prognosis in 61 confirmed and suspected COVID-19 patients with lopinavir/ritonavir were analyzed.

RESULTS:

Among the 61 patients, 41(67.21%) had lopinavir/ritonavir related side effects, mainly manifested as gastrointestinal reactions (82.93%) and liver function damage (53.66%). Old age, long course of disease and chronic gastrointestinal disease are independent risk factors for side effects.

CONCLUSION:

Lopinavir/ritonavir has a high incidence of side effects and can be used in COVID-19 patients under the condition of close observation of the patient's symptoms and test results. Special population should improve pharmaceutical care to ensure the safety of drug use.

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Experimental Studies Language: Chinese Journal: Chinese Journal of Clinical Pharmacology and Therapeutics Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Experimental Studies Language: Chinese Journal: Chinese Journal of Clinical Pharmacology and Therapeutics Year: 2020 Document Type: Article